Intellectual Property Law
New Matter SUMMER 2017 Volume 42, Number 2
Content
- 2017 New Matter Author Submission Guidelines
- Case Comments
- Copyright Commentary
- Federal Circuit Report
- Federal Government Expands Public Disclosure Requirements For Clinical Trials: Product Developers Must Publish More Detailed Information, Study Protocols, and the Results of Studies of Unapproved/Unmarketed Products
- Intellectual Property Section Executive Committee 2016-2017
- Intellectual Property Section Interest Group Representatives 2016-2017
- Ip and Art: An International Perspective
- Letter from the Chair
- Letter from the Editor-in-Chief
- Ninth Circuit Report
- Online Cle For Participatory Credit
- Standing Still: Denial of Certiorari in Belmora Llc v. Bayer Consumer Care Ag Leaves Question on Standing for Foreign Plaintiff's Unfair Competition Claims
- The Band Who Must Not Be Named: Summary of Briefs and Oral Hearing in Lee v. Tam
- The Licensing Corner
- The State Bar of California Intellectual Property Alumni
- Ttab Decisions and Developments
- Contents
Contents
3 Letter from the Chair
Elizabeth J. Rest
4 Letter from the Editor-in-Chief
Thomas A. Ward
5 Federal Government Expands Public
Disclosure Requirements For Clinical
Trials: Product Developers Must Publish
More Detailed Information, Study
Protocols, and the Results of Studies of
Unapproved/Unmarketed Products
Christina M. Markus
Beverly H. Lorell, M.D.
Elaine H. Tseng
10 Standing Still: Denial of Certiorari in
Belmora LLC v. Bayer Consumer Care AG
Leaves Question on Standing for Foreign
Plaintiff’s Unfair Competition Claims
Anna Raimer
Meredith Wilkes